The technology was developed in partnership with the United States Army Institute of Surgical Research, San Antonio Military Medical Center at Fort Sam Houston and Ohio State University. The project is part of Arteriocyte’s Cellular Therapies for Battlefield Wounds Program.
The Magellan system is cleared for the rapid production of platelet-rich plasma from blood and bone marrow, which can be applied to a surgical site. The current clinical protocol will assess the technology’s role in treating wounded military personnel who are at risk for long-term complications as a result of compartment syndrome.
More Articles on Orthopedic Devices:
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in March
Synthes & Generic Implant Company CEO Trade Lawsuits
Amedica Launches Allograft Products for Spinal Surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.